HealthInvest Partners AB purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,617 shares of the company's stock, valued at approximately $1,662,000. Neurocrine Biosciences comprises approximately 1.3% of HealthInvest Partners AB's portfolio, making the stock its 22nd biggest holding.
A number of other hedge funds and other institutional investors also recently modified their holdings of NBIX. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences during the 1st quarter worth about $27,000. Headinvest LLC bought a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $28,000. KB Financial Partners LLC bought a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $32,000. BluePath Capital Management LLC bought a new stake in Neurocrine Biosciences in the 3rd quarter valued at $35,000. Finally, Covestor Ltd grew its holdings in Neurocrine Biosciences by 431.0% in the 1st quarter. Covestor Ltd now owns 377 shares of the company's stock valued at $35,000 after buying an additional 306 shares in the last quarter. Institutional investors own 92.59% of the company's stock.
Neurocrine Biosciences Price Performance
Shares of NBIX stock traded up $1.25 on Tuesday, reaching $132.99. 1,033,219 shares of the company were exchanged, compared to its average volume of 854,839. Neurocrine Biosciences, Inc. has a one year low of $89.04 and a one year high of $148.37. The company has a market cap of $13.23 billion, a price-to-earnings ratio of 54.44 and a beta of 0.25. The company has a 50-day moving average of $136.45 and a 200-day moving average of $126.62.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same period last year, the firm earned $0.88 earnings per share. The business's quarterly revenue was up 25.0% compared to the same quarter last year. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current year.
Analyst Ratings Changes
A number of analysts have issued reports on NBIX shares. StockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. Citigroup cut their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating for the company in a research report on Thursday, February 8th. The Goldman Sachs Group upped their price objective on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a "buy" rating in a research report on Thursday, January 25th. Mizuho boosted their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, February 8th. Finally, Barclays raised their price objective on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Tuesday, January 23rd. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $139.25.
Check Out Our Latest Report on NBIX
Insider Activity at Neurocrine Biosciences
In other news, Director Richard F. Pops sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the transaction, the director now owns 29,512 shares in the company, valued at approximately $3,909,454.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now owns 29,512 shares of the company's stock, valued at $3,909,454.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Ingrid Delaet sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the sale, the insider now owns 7,507 shares of the company's stock, valued at approximately $1,088,965.42. The disclosure for this sale can be found here. In the last three months, insiders sold 177,176 shares of company stock valued at $24,562,081. 4.60% of the stock is owned by insiders.
About Neurocrine Biosciences
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
